



## **MICRO INVASIVE TECHNOLOGY, INC.**

**Vol. 2, No.1**  
**February 15, 2007**

We have completed development of our first **DirectView** endoscopes. This is the first in a series of endoscopic instruments in the **DirectView** family. These instruments combine high quality imaging with disposability and improved ease-of-use. We are in the process of filing for FDA approval for our **DirectView** disposable endoscopic system in anticipation of a staged product entry into the medical/surgical product markets. We continue to refine our endoscope to meet FDA requirements.

Initial testing of our **TheraScope™** lightwave technology has been successfully completed at the Public Health Research Institute at Rutgers University. Exciting photographs on the reverse side of this newsletter dramatically illustrate this technology's effectiveness in eradicating infectious antibiotic-resistant bacteria.

We are continuing to build on our strategic partnership with Dr. Barry Krieswirth and his Team at PHRI. The Team will be using MITI therapeutic equipment to conduct additional tests on the ability of our lightwave technology to eradicate various strains of antibiotic-resistant pathogens. John Bala will be working closely with PHRI to design specific test protocols.

We are expanding our **TheraScope™** product line to include development of a therapeutic lightwave blood and bladder catheter system where long term catheter use causes serious infection. Other therapeutic products under development are a topical scanner for killing pathogens impacting open burns and wounds; and a therapeutic nasal endoscope for eradication of bacteria in the nose, the site where most infections enter the body.

This past January, John Bala presented the PHRI photographs, and the results which they signify, to a panel of international experts at the BIOS 2007 Biotechnology Symposium in San Jose, CA. The paper, **Multispectral Therapeutic Endoscopy**, which John co-authored with our medical advisor, Dr. Steve Schwaitzberg, will be published in the Symposium's *Proceedings*.

MITI has also established a new, collaborative alliance with Resonant Sensors, Inc., a Texas research firm which develops real-time, microbial sensing equipment that detects the presence of infection within the body. We will be collaborating with its Founder, Debra Wawro, to study the effects of our lightwave technology on bio-films and other pathogens. This research will compliment PHRI's research efforts.

At the end of this month, our Board of Directors will meet to discuss the Company's future direction, and to nominate a slate of Directors for you to vote on at our upcoming Shareholders' Meeting. The date of this meeting, expected to be at the end of March, will also be set at that time.

You will receive an invitation to this meeting, with an enclosed proxy, within a few weeks. This package will also include a copy of our new, one page brochure. Let us know what you think! Should you wish to attend the Shareholders' Meeting, MITI will pay the cost of one night at a hotel.

After the Shareholders' Meeting, we will again update our website. This update will include more information about the Directors which you elect, and a new section detailing our anti-microbial research.

## **TheraScope™ THERAPEUTIC PRODUCTS**


**TheraScope™ Antimicrobial Intervention Capability** is a complete departure from current technology. Its objective is to direct therapeutic lightwaves to either a localized area within the body, or onto external surface tissue to destroy antibiotic-resistant infectious bacteria. Once this technology achieves FDA pre-market clinical approval, MITI will showcase a vital new modality that combines imaging capability with therapeutic intervention. To expand and enhance our credibility in medical markets, we are currently seeking \$1.5 million in NIH grants to continue our research.

Our **Therapeutic Lightwave Catheter System** will be designed to eradicate pathogens which can infect a patient's blood and/or bladder catheters as well as breathing tubes. Because of extended use, these devices are subject to frequent, and serious, foreign body infections. Our **Therapeutic Lightwave Scanner** will eradicate surface bacteria from burns, cuts and wounds with no tissue contact within seconds of lightwave exposure. This instrument could also be used to disinfect surgical entrance/exit sites. The product will be designed for hospitals, nursing homes, outpatient clinics and doctors' offices; but could also significantly augment EMT and ambulance capability, providing antimicrobial therapy long before drug therapy might be administered to a patient.

### **ANTIMICROBIAL RESULTS**

The assay plates in the photographs shown below contain large colonies of antibiotic-resistant *Staphylococcus* and *Pseudomonas* bacteria; the clear circles indicate where bacteria have been completely eradicated with lightwaves by a 5 second exposure to therapeutic wavelengths. Longer exposure neither increased effectiveness nor made any difference in the results.

***Staphylococcus aureus***



***Pseudomonas aeruginosa***



Working with the Team at Public Health Research Institute at Rutgers University, MITI has also tested other antibiotic-resistant pathogens, including *Acinetobacter*, *Bacillus subtilis*, *Klebsiella pneumoniae*, *Escherichia coli* and *Helicobacter pylori*. An aggressive strain of *Acinetobacter baumannii*, brought from Iraq by returning veterans that is causing major problems in civilian and VA hospitals, was also successfully eradicated. We have also tested our therapeutic lightwave technology on *Aspergillus*, fungus and some viruses, with the same results of total eradication.

***Acinetobacter baumannii***



***Klebsiella pneumoniae***



***Aspergillus fumigatus***



Our strategic relationships with leading-edge surgeons and bio-tech specialists indicate a high degree of confidence in our ability to efficiently eradicate pathogens without drugs, and to achieve significant penetration of the surgical markets. MITI's unique intellectual property and proprietary technology position the Company to become an important and player in healthcare delivery. We firmly believe that the outlook for MITI's future justifies your confidence in our ability to deliver significant financial and healthcare dividends.